Latest stories on TRDA
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
GlobeNewswire52 · neutralgeneral
TRDA Moves Toward Its Top Dose in ELEVATE-44-201 After DMC Backs 18 mg/kg Cohort 3
MarketChameleon63 · neutralproduct/pr
Entrada Therapeutics, Inc. (TRDA) files 8-K
SEC 8-K50 · neutralgeneral
Entrada Therapeutics reports data from Cohort 1 of ELEVATE-45-201 clinical study
The Fly62 · neutralproduct/pr
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Business Insider63 · neutralproduct/pr
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
GlobeNewswire50 · neutralgeneral
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
Business Insider50 · neutralgeneral
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Entrada Therapeutics reports Q2 results
Seeking Alpha34 · bearishearnings
Entrada Therapeutics, Inc. (TRDA) files 8-K
SEC 8-K50 · neutralgeneral
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
StockTitan50 · neutralgeneral
Entrada Therapeutics Stockholders Approve Directors and Equity Plans
TipRanks50 · neutralgeneral
Entrada Therapeutics, Inc. (TRDA) files 8-K
SEC 8-K50 · neutralgeneral
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha56 · neutralgeneral
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TRDA Stock News
StockTitan50 · neutralgeneral
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
TipRanks73 · bullishproduct/pr